2012-09-17 06:08:51 - New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Global Markets Direct's, 'Brain Cancer - Pipeline Review, H2 2012', provides an overview of the Brain Cancer therapeutic pipeline. This report provides information on the therapeutic development for Brain Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Cancer. 'Brain Cancer - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/463888_brain_cancer_pipeline_review_h2_2012. ..


Note*: Certain sections in the report may be removed or altered based on the availability

and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Brain Cancer.
* A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Brain Cancer pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Brain Cancer.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Brain Cancer pipeline depth and focus of Brain Cancer therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Brain Cancer Therapeutic Products under Development, Key Players in Brain Cancer Therapeutics, Brain Cancer Pipeline Overview, Brain Cancer Pipeline, Brain Cancer Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Brain Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Brain Cancer
Brain Cancer Therapeutics under Development by Companies
Brain Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Brain Cancer Therapeutics - Products under Development by Companies
Brain Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Brain Cancer Therapeutics Development
United Therapeutics Corporation
Sanofi-Aventis
Eli Lilly and Company
Novartis AG
Dong-A Pharmaceutical Co., Ltd.
Nippon Shinyaku Co., Ltd.
Pfizer Inc.
Alfacell Corporation
Advaxis, Inc.
Neuralstem, Inc.
Lixte Biotechnology Holdings, Inc.
Bionomics Limited
Critical Outcome Technologies Inc.
Prana Biotechnology Limited
Diamyd Medical AB
e-Therapeutics plc
AngioChem Inc.
Pervasis Therapeutics, Inc.
PTC Therapeutics, Inc.
Stemline Therapeutics, Inc.
Kinex Pharmaceuticals, LLC
to-BBB technologies BV
Archer Biosciences, Inc
ArmaGen Technologies, Inc.
VectorLogics, Inc.
Brain Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
NC3 - Drug Profile
Bafetinib - Drug Profile
BSI-201 - Drug Profile
COTI-2 - Drug Profile
AC 03-636 - Drug Profile
8H9 MAb - Drug Profile
SL-302 - Drug Profile
SL-301 - Drug Profile
SL-301 - Drug Profile
DA-3607 - Drug Profile
2.5-Dimethyl-Celecoxib - Drug Profile
Vorinostat + Bevacizumab + Temozolomide - Drug Profile
ADXS-HER2 - Drug Profile
CST-102 - Drug Profile
PTC-299 - Drug Profile
Valproate + Etoposide - Drug Profile
Bortezomib + Temozolomide - Drug Profile
AdV-tk + Valacyclovir + Radiation Therapy - Drug Profile
BNC105 - Drug Profile
ETS2101 - Drug Profile
Melphalan - Drug Profile

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463888&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.